Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

NCT04280081 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04280081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04280081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 16, 2020
Completion date
November 30, 2028
Enrollment
77 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer, solid tumor